GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (FRA:3DMA) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Kintara Therapeutics (FRA:3DMA) Future 3-5Y EPS without NRI Growth Rate : 64.43 (As of May. 21, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate is 64.43.


Competitive Comparison of Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Kintara Therapeutics  (FRA:3DMA) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Kintara Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics Business Description

Industry
Traded in Other Exchanges
N/A
Address
9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines